Gyroscope Therapeutics Holdings plc Share Price

VISN

US40382N1037

Biotechnology & Medical Research

Latest news: Gyroscope Therapeutics Holdings plc

23/22/23	Gyroscope Therapeutics Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021	CI
18/22/18	Novartis AG acquired Gyroscope Therapeutics Holdings plc on February 18, 2022	CI
22/21/22	Syncona Shares Rise After Novartis Agrees to Buy Portfolio Company	DJ
22/21/22	Novartis to Acquire Gyroscope Therapeutics for Up to $1.5 Billion	DJ
22/21/22	Novartis AG signed an agreement to acquire Gyroscope Therapeutics Holdings plc for £1.1 billion.	CI
08/21/08	Syncona Says Sanofi to Invest up to $60 Million in Gyroscope Therapeutics	DJ
08/21/08	Gyroscope Therapeutics Holdings plc announced that it expects to receive £44.5 million in funding from Sanofi Ventures	CI
30/21/30	Gyroscope Therapeutics Holdings plc Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting	CI
22/21/22	Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids	CI
07/21/07	Gyroscope Therapeutics Holdings plc has withdrawn its IPO in the amount of $148.5 million.	CI
16/21/16	Gyroscope Therapeutics Holdings plc has filed an IPO in the amount of $100 million.	CI
11/21/11	Gyroscope Therapeutics Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
11/19/11	Gyroscope Therapeutics Limited acquired Orbit Biomedical Inc. from Syncona Portfolio Ltd and other shareholders.	CI

More news

Managers and Directors: Gyroscope Therapeutics Holdings plc

Manager	Title	Age	Since
Ian Pitfield CTO	Chief Tech/Sci/R&D Officer	60	01/07/2020
Jane Hughes CTO	Chief Tech/Sci/R&D Officer	52	01/10/2019
Edward Lang PRN	Corporate Officer/Principal	46	01/06/2019

Director	Title	Age	Since
Chinmay Umesh Bhatt BRD	Director/Board Member	53	17/02/2022
Jason Mark Brooks BRD	Director/Board Member	54	17/02/2022
Janet Hopkins BRD	Director/Board Member	61	17/02/2022

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GYROSCOPE THERAPEUTICS HOLDINGS PLC	-.--%	-.--%	-	-	61Cr
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	6.35TCr
ARGENX SE	+1.76%	+2.10%	+12.10%	+81.21%	5.45TCr
LONZA GROUP AG	-0.94%	+0.77%	+8.85%	+100.19%	5.36TCr
IQVIA HOLDINGS INC.	+2.76%	+4.18%	+28.34%	+55.07%	4.48TCr
BEONE MEDICINES AG	+2.00%	-2.90%	+18.37%	+119.04%	4.16TCr
REVOLUTION MEDICINES, INC.	+1.34%	-3.98%	+225.44%	+914.08%	3.99TCr
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	3.25TCr
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	2.67TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	2.34TCr
Average	+4.08%	-0.42%	+52.16%	+162.82%	4.23TCr
Weighted average by Cap.	+3.21%	-0.29%	+47.56%	+161.47%

See all sector performances

Gyroscope Therapeutics Holdings plc, formerly Gyroscope Therapeutics Holdings Limited, is a clinical-stage gene therapy company. The Company develop gene therapy beyond rare diseases. It offers therapies to treat diseases of the eye that cause vision loss and blindness. The Company's investigational gene therapy, GT005, is in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a cause of blindness. The Company develops a pipeline of recombinant adeno-associated virus (rAAV), vector-based gene therapy candidates targeting genetic variants in the pathway to be key drivers of AMD. Its gene therapies are designed as one-time treatments. The Company's lead programs, GT005 and GT011, focus on two key targets such as Complement Factor I (CFI) and factor H like-1 (FHL1), a variant of Complement Factor H (CFH). Its gene therapy, GT005, is designed to restore balance to a system by production of CFI, a regulatory protein.

Employees

179

Sector

Biotechnology & Medical Research

More about the company